irix-ex991

MOUNTAIN VIEW, Calif., May 11, 2021 -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 3, 2021.

“We enjoyed a strong start to 2021 and our positive momentum continued with revenue that exceeded pre-COVID levels, setting a record for first quarter revenue. During the quarter, we saw international adoption of our Cyclo G6 probes rebound strongly, leading to a new first quarter high in Cyclo G6 probe sales. Additionally, we saw strong performance in our retina business, which was further bolstered by the initial sales of PASCAL products acquired from Topcon,” said David I. Bruce, President and CEO of Iridex.

“The investments we made in our product portfolio over the past year and a half are really starting to pay off for the company, particularly with respect to our enhanced retina products. Our focus is now shifting to expand our sales and marketing programs, where we are broadening efforts to demonstrate the many benefits of our non-incisional glaucoma therapy. We intend to leverage our strengthened balance sheet following the Topcon transaction, and pursue the expanding global opportunities we see in both our glaucoma and retina product portfolios,” concluded Bruce.

Revenue for the three months ending April 3, 2021 increased 33% to $12.0 million from $9.0 million during the same period of the prior year. Excluding newly acquired PASCAL products, revenue increased 19% over the first quarter of 2020.

Gross profit for the first quarter of 2021 increased to $4.9 million, a 41% gross margin, compared to $3.9 million, a 43% gross margin, in the same period last year. The gross margin reduction was primarily attributable to a higher portion of revenue coming from wholesale capital equipment sales.

Operating expenses for the first quarter of 2021 increased 22% to $6.8 million compared to $5.6 million in the same period of the prior year, mainly due to additional expenses in PASCAL operations and non-recurring Topcon transaction and integration expenses.

Net Loss for the first quarter of 2021 was $2.0 million, compared to $1.7 million in the same period of the prior year. Net Loss on a per share basis was $0.14 versus $0.12 last year.

Cash usage in the first quarter was $1.1 million, including approximately $0.5 million of non-recurring Topcon transaction payments, which resulted in cash of $28 million at quarter-end.

Iridex expects total revenue for fiscal year 2021 to be $48 million to $51 million, reflecting growth of 32% - 40% over fiscal year 2020. In addition, Cyclo G6 probe sales of 56,000 to 59,000 and Glaucoma Laser System sales of 250 to 275 are expected in 2021.

Iridex’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 1282162. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website: www.iridex.com.

About Iridex
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the future momentum, demand and utilization of the Company's products, financial guidance, expected sales volumes and benefits from the Topcon partnership. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 2, 2021, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

	Three Months Ended
	April 3,			March 28,
	2021			2020

Total revenues	$	11,959		$	9,021
Cost of revenues		7,020			5,105
Gross profit		4,939			3,916

Operating expenses:
Research and development		1,165			719
Sales and marketing		2,982			3,152
General and administrative		2,633			1,698
Total operating expenses		6,780			5,569

Loss from operations		(1,841	)		(1,653	)
Other (expense) income, net		(161	)		9
Loss from operations before provision for income taxes		(2,002	)		(1,644	)
Provision for income taxes		8			7
Net loss	$	(2,010	)	$	(1,651	)

Net loss per share:
Basic	$	(0.14	)	$	(0.12	)
Diluted	$	(0.14	)	$	(0.12	)

Weighted average shares used in computing net loss per share
Basic		14,346			13,786
Diluted		14,346			13,786

	April 3,			January 2,
	2021			2021
Assets
Current assets:
Cash and cash equivalents	$	27,993		$	11,626
Accounts receivable, net		8,185			7,289
Inventories		7,042			5,714
Prepaid expenses and other current assets		1,001			730
Total current assets		44,221			25,359
Property and equipment, net		719			449
Intangible assets, net		2,349			68
Goodwill		965			533
Operating lease right-of-use assets, net		1,228			1,428
Other long-term assets		77			132
Total assets	$	49,559		$	27,969

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	1,687		$	1,148
Accrued compensation		1,873			1,965
Accrued expenses		1,447			990
Other current liabilities		2,274			816
Current portion of PPP loan		2,185			1,249
Accrued warranty		124			166
Deferred revenue		1,812			938
Operating lease liabilities		1,345			1,409
Total current liabilities		12,747			8,681

Long-term liabilities:
PPP loan		312			1,248
Accrued warranty		81			81
Deferred revenue		10,653			289
Operating lease liabilities		95			282
Other long-term liabilities		22			22
Total liabilities		23,910			10,603

Stockholders' equity:
Common stock		165			148
Additional paid-in capital		84,419			74,181
Accumulated other comprehensive income (loss)		19			(19	)
Accumulated deficit		(58,954	)		(56,944	)
Total stockholders' equity		25,649			17,366

Total liabilities and stockholders' equity	$	49,559		$	27,969